Zanoni, Michele http://orcid.org/0000-0003-1826-9430
Sarti, Alba Clara
Zamagni, Alice
Cortesi, Michela
Pignatta, Sara http://orcid.org/0000-0001-5464-0052
Arienti, Chiara http://orcid.org/0000-0002-2265-828X
Tebaldi, Michela
Sarnelli, Anna http://orcid.org/0000-0001-5986-3845
Romeo, Antonino
Bartolini, Daniela
Tosatto, Luigino
Adinolfi, Elena http://orcid.org/0000-0001-8129-9929
Tesei, Anna http://orcid.org/0000-0002-8351-5952
Di Virgilio, Francesco http://orcid.org/0000-0003-3566-1362
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG16812, IG22837, IG 13025, IG 18581, IG 22883)
Ministero della Salute (RF-2011-02348435)
Article History
Received: 25 August 2021
Revised: 17 December 2021
Accepted: 11 January 2022
First Online: 24 January 2022
Competing interests
: Francesco Di Virgilio is a member of the Scientific Advisory Board of Biosceptre Ltd, a UK-based company involved in the development of P2X7-targeted antibodies. The remaining authors declare no competing interests.